Drug updated on 10/23/2023

Dosage FormInjection (intravenous: 50 mg, 100 mg)
Drug ClassTissue plasminogen activator (tPA)
Ongoing and
Completed Studies


  • For the treatment of Acute Ischemic Stroke (AIS).
  • For the treatment of Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure.
  • For the treatment of Acute Massive Pulmonary Embolism (PE) for lysis.

Product Monograph / Prescribing Information

Document TitleYearSource
Activase (alteplase) Prescribing Information.2022Genentech, Inc. A Member of the Roche Group, South San Francisco, CA
Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: a pairwise and network meta-analysis of randomized controlled trials.2022Journal of the Neurological Sciences

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines